Pyxis Oncology, Inc. (PYXS)
| Market Cap | 190.70M +196.0% |
| Revenue (ttm) | 11.04M +291.4% |
| Net Income | -88.73M |
| EPS | -1.40 |
| Shares Out | 63.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 700,661 |
| Open | 2.990 |
| Previous Close | 3.010 |
| Day's Range | 2.862 - 3.080 |
| 52-Week Range | 1.030 - 5.550 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 7.22 (+139.87%) |
| Earnings Date | Aug 13, 2026 |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o... [Read more]
Financial Performance
In 2025, Pyxis Oncology's revenue was $13.86 million, a decrease of -14.17% compared to the previous year's $16.15 million. Losses were -$79.62 million, 2.96% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price target is $7.22, which is an increase of 139.87% from the latest price.
News
Pyxis Oncology Slides: Corporate presentation
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data...
Pyxis Oncology Quarterly report: Q2 2026
Pyxis Oncology has published its Q2 2026 quarterly earnings report on August 13, 2026.
Pyxis Oncology Earnings release: Q2 2026
Pyxis Oncology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Pyxis Oncology initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $12 price target The firm says dose capping likely addresses concerns on Micvo’s safety. In addition, the…
Pyxis Oncology announces up to $114M private placement
Pyxis Oncology (PYXS) announced that it has entered into definitive securities purchase agreements for a private placement expected to result in gross proceeds of approximately $50M, before deducting ...
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap
Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2026
A novel ADC targeting the tumor stroma is advancing in head and neck cancer, with mid-year data to clarify efficacy, safety, and regulatory path. Dose capping addresses safety in high body weight patients, and combination strategies are underway.
Pyxis Oncology Transcript: Stifel 2026 Targeted Oncology Virtual Forum
MICVO, an ADC targeting EDB-FN, has shown strong efficacy in head and neck cancer, with a 46–50% response rate at high doses and promising safety improvements via dose capping. Key monotherapy and combination data updates are expected mid-year and in the second half of the year.
Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026
MICVO, a novel ADC, has shown strong efficacy in second-line head and neck cancer, with a 46% response rate and promising safety improvements through dose capping. Ongoing trials and translational research support its potential in combination therapies and broader cancer indications.
Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)
“Our team’s exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm for MICVO’s potential to positively impact the lives of patients ...
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focu...
Pyxis Oncology Quarterly report: Q1 2026
Pyxis Oncology has published its Q1 2026 quarterly earnings report on May 14, 2026.
Pyxis Oncology Earnings release: Q1 2026
Pyxis Oncology released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that mana...
Pyxis Oncology Slides: Investor presentation
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appoi...
Wedbush bullish on Pyxis Oncology, initiates with an Outperform
As previously reported, Wedbush analyst Robert Driscoll initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and $6 price target The firm notes that the company’s lead program micvota...
Pyxis Oncology initiated with an Outperform at Wedbush
Wedbush initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and $6 price target
Pyxis Oncology Proxy statement: Proxy filing
Pyxis Oncology filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Pyxis Oncology Proxy statement: Proxy filing
Pyxis Oncology filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC
Pyxis Oncology price target lowered to $8 from $9 at Stifel
Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $8 from $9 and keeps a Buy rating on the shares. The firm is “encouraged” by management’s completion in…
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quar...
Pyxis Oncology Earnings release: Q4 2025
Pyxis Oncology released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.